Sri Sahasranaman is Senior Vice President of Clinical Pharmacology at Prelude Therapeutics and is responsible for leading and overseeing clinical pharmacology and pharmacometrics strategies to facilitate clinical development of assets. Before joining Prelude, Sri built and scaled up the Global Clinical Pharmacology organization at BeiGene (now BeOne) for six years. Previously, Sri worked at Genentech, Novartis and Sanofi and has over 20 years of drug development experience in multiple therapeutic areas including oncology, neuroscience and respiratory. He has provided clinical pharmacology leadership for four NDA/BLA and multiple sNDA/sBLA filings in his career. Sri received his B. Pharm (Hons.) degree from BITS Pilani, India, M.S. in Pharmacy from the National University of Singapore and Ph.D. in Pharmaceutical Sciences from the University of Florida. His areas of professional and research interest include innovative dose optimization approaches in oncology, leveraging global clinical data to bridge efficacy and safety across regions, formulation bridging and pediatric drug development in oncology.